| Filed On | Filing |
|---|---|
| 05 Dec 2025 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On October 21, 2025, the Company eliminated the positions of Chief Commercial Officer and General Counsel, effective December 1, 2025, in connection with a broader organizational restructuring of the Company. The Company notified Kerr Ho... |
| 28 Apr 2025 |
8-K/A: Departure/Election of Directors or Officers; Compensation
Based on the discussions with the Board of Directors, this amendment will memorialize the changes to the role and compensation of your original offer letter that have gone into effect. |
| 18 Apr 2025 |
8-K/A: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025. |
| 21 Feb 2023 |
8-K/A: Costs Associated with Exit or Disposal Activities
As previously announced, on January 10, 2023, the Company approved the Transformation Process, pursuant to which the Company plans to: (i) combine its Chronic Care and Pain franchises into a single commercial organization focused on the ... |
| 10 Apr 2017 | 8-K/A: Regulation FD Disclosure |
Loading...
